Clinical trials · Pennsylvania
Prostate cancer clinical trials in Pennsylvania
We’re tracking 81 recruiting prostate cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Hershey, PennsylvaniaAges 18 years+ - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06138067Recruiting
Navigator program to help cancer patients join clinical trials
This study tests if a patient navigator can help more people with prostate or kidney cancer enroll in clinical trials. You may be assigned to work with a navigator who helps find a trial that fits your needs.
Chambersburg, PennsylvaniaAges 18 years+ - NCT05001477Recruiting
Registry for men receiving TULSA-PRO prostate treatment
This is a study registry that collects information from men who are going to receive TULSA-PRO treatment. It helps researchers understand how the treatment is used and what outcomes people experience.
York, PennsylvaniaAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05629494RecruitingPhase 4
Ibuprofen vs PSA blood test for prostate evaluation
This trial studies whether an anti-inflammatory medicine (ibuprofen) changes prostate-specific antigen (PSA) blood test results to help decide on next diagnostic steps like MRI or biopsy. It may help people with an elevated PSA understand whether follow-up testing is more or less likely to be needed.
Hershey, PennsylvaniaAges 18–80 - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06659614Recruiting
Prostate tissue collection for future cancer research
This study collects prostate tissue samples from men who are either at higher risk due to a gene change or are getting a biopsy or prostate surgery for routine care. The samples are stored in a biobank for future research on prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06064149Recruiting
Heart risk study for men on hormone therapy for prostate cancer
This study looks at heart health in men with prostate cancer who are taking or will take hormone therapy (ADT) for at least 6 months. It aims to learn more about cardiovascular risks and how to manage them.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Monroeville, PennsylvaniaAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06095089RecruitingPhase 1
Study of two drugs for advanced prostate cancer
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Allentown, PennsylvaniaAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06511141Recruiting
Nerve stimulation for men with overactive bladder
This study tests a nerve stimulation device placed near the tailbone to help men with overactive bladder symptoms. If you have bothersome urinary urgency or frequency, this treatment may offer relief without drugs.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06296147Recruiting
Virtual reality or aromatherapy for prostate biopsy
This study tests if using a virtual reality headset or an aromatherapy patch can help reduce anxiety or discomfort during a prostate biopsy. If you are scheduled for this procedure, you may be able to join.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Allentown, PennsylvaniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04175431RecruitingPhase 2
PSMA or FACBC PET scan guided treatment for prostate cancer recurrence
This Phase 2 study tests using a special PET/CT scan (PSMA or FACBC) to guide treatment for prostate cancer that has come back after surgery and radiation. The goal is to see whether this scan-based approach can better target cancer in the prostate area (and help plan the right treatment).
Pittsburgh, PennsylvaniaAges 18 years+
Prostate cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting prostate cancer studies listed above.
- MidLantic Urology · 5 studies
- Thomas Jefferson University Hospital · 4 studies
- University of Pittsburgh Medical Center · 4 studies
- University of Pennsylvania · 3 studies
- Allegheny General Hospital · 2 studies
- Allegheny Health Network Saint Vincent Hospital · 2 studies
- Forbes Hospital · 2 studies
- Fox Chase Cancer Center · 2 studies
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate cancer trials in other states
Common questions
- Are there prostate cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 81 recruiting prostate cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.